CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reports that its CEO purchased 3,500 shares of CTTH on September 10, 2026 at a price of $0.05 per share in a direct, non-derivative open-market or private transaction. Following this purchase, the CEO directly holds 9,400,556 shares of CTTH. No Rule 10b5-1 trading plan is reported for this transaction.
CTT Pharmaceutical Holdings, Inc. (CTTH), acting in a reporting officer capacity, reported a purchase of 9,800 shares of CTTH common stock on September 4, 2026 at $0.0489 per share. Following this open-market or private transaction, direct holdings increased to 9,397,056 shares.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported that it purchased 3,000 shares of its CTTH security on September 2, 2026, in a non-derivative open market or private transaction at a price of $0.0489 per share. Following this purchase, the reporting holder directly owns 9,387,256 shares.
No Rule 10b5-1 trading plan is reported for this transaction.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported that its CEO purchased shares of the company’s common stock. On 2026-08-31, the reporting person bought 3,500 shares of CTTH in a purchase described as an open market or private transaction at $0.049 per share, bringing the reported direct holdings to 9,384,256 shares.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH), as reporting person, disclosed a purchase of its CTTH common stock. On 2026-08-24, it purchased 2,100 shares at a price of $0.055 per share in an open market or private transaction, bringing the reported directly held position to 9,360,756 shares after the transaction.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported an insider purchase of its own common stock. On 2026-08-20, the reporting person acquired 11,500 shares of CTTH in an open market or private transaction at $0.045 per share, resulting in 9,378,656 shares held directly after the transaction.
CTT Pharmaceutical Holdings, Inc. (CTTH) reported an insider purchase of its common stock. The reporting person, listed as CTT Pharmaceutical Holdings, Inc. in its capacity as CEO, purchased 10,000 CTTH shares on 2026-08-19 at $0.059 per share in an open-market or private transaction. Following this transaction, the filing reports 9,365,456 shares of CTTH common stock held with direct ownership.
CTT Pharmaceutical Holdings, Inc. (CTTH), reporting as CEO, purchased 1,800 shares of its common stock on 2026-08-14 in an open-market or private transaction at $0.062 per share. Following this transaction, the reporting holder directly owns 9,355,456 shares of CTTH.
CTT Pharmaceutical Holdings, Inc. reports that the U.S. Patent and Trademark Office has approved a continuation-in-part patent for its micelle-based delivery technology, effective August 11, 2026. The patent adds protection for formulations delivering nicotine, vitamins, and caffeine and supports multiple dosage forms, including dissolvable strips, gum, pouches, lozenges, and dissolving tablets. The company describes this as part of its strategy to strengthen its patent portfolio around oral drug delivery systems designed for rapid onset, patient convenience, and efficient absorption across pharmaceutical, therapeutic, and nutraceutical markets.
CTT Pharmaceutical Holdings, Inc. reported that its CEO purchased 7,700 CTTH shares on August 7, 2026 in a non-derivative open market or private transaction at $0.065 per share. Following this purchase, the CEO directly owns 9,353,656 shares of CTTH. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.